15 November 2017 - - San Francisco, California-based precision medicine solutions specialist Syapse has raised USD30 m in Series D financing, which will enable the company to expand operations and bring its precision medicine solutions to more providers and their cancer patients, the company said.
Participants include existing investors Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital, as well as new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.
With precision medicine, physicians can deliver personalized cancer care based on a patient's clinical and genomic profile, an approach that has been shown to improve care, lower costs, and increase efficiency.
In addition to enabling precision medicine at more community health systems, Syapse's expansion will allow its customers to increase patient access to clinical trials.
Syapse's software platform, data sharing network, and industry partnerships bring healthcare innovators together into a unified ecosystem, and enable healthcare providers to bring precision cancer care to every patient who needs it.
The company's customers manage one million active cancer cases at nearly 300 hospitals in 25 states.